Gain Therapeutics to Participate in the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference
04/26/2022 - 05:18 PM
BETHESDA, Md., April 26, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming the drug discovery paradigm with structurally targeted allosteric regulators identified with its proprietary computational discovery platform, today announced that Chief Executive Officer Eric Richman will participate in a fireside chat during the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference, and invites investors to participate via webcast. Please see additional details below:
B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference Format: Fireside Chat Date: Thursday, April 28, 2022 Time: 2:00 p.m. to 2:30 p.m. ET Webcast: Registration link
A live webcast of the virtual presentation can be accessed through the Events section of the Company’s website at https://www.gaintherapeutics.com/investors-media/overview.html . An archived replay of the webcast will be available on the Company’s website following the live presentation.
About Gain Therapeutics, Inc. Gain Therapeutics, Inc. is transforming the drug discovery paradigm with structurally targeted allosteric regulators identified with its proprietary computational discovery platform SEE-Tx®. The ability to identify never-seen-before allosteric targets on proteins involved in diseases across the full spectrum of therapeutic areas provides opportunities for a range of drug-protein interactions, including protein stabilization, protein destabilization, targeted protein degradation, allosteric inhibition and allosteric activation. Gain’s pipeline spans neurodegenerative diseases, lysosomal storage disorders, metabolic diseases and oncology. Gain’s lead program in Parkinson’s disease has been awarded funding support from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse. For more information, please visit https://www.gaintherapeutics.com .
Investor & Media Contacts:
Gain Therapeutics Investor Contact: Noor Pahlavi Argot Partners (212) 600-1902Gain@argotpartners.com
Gain Therapeutics Media Contact: Joleen Schultz Joleen Schultz & Associates +1 760-271-8150joleen@joleenschultzassociates.com
GANX Rankings
#2931 Ranked by Stock Gains
GANX Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
About GANX
gain therapeutics is a preclinical stage biotech company specializing in the discovery of new drugs for orphan diseases. the company targets inborn errors of metabolism; a group of rare diseases of genetic origin with a high unmet medical need. gain therapeutics is also working on a new class of compounds: non-competitive pharmacological chaperones, identified through its innovative proprietary platform – see-tx. the gain therapeutics team is made up of a group of drug discovery and development experts with several decades of experience in biotech and pharma.